Current Report Filing (8-k)
07 May 2019 - 6:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (date of earliest event reported):
April 30, 2019
HealthLynked
Corp.
(Exact Name of Registrant as Specified in its Charter)
Nevada
|
|
47-1634127
|
(State of Incorporation)
|
|
(I.R.S. Employer Identification No.)
|
|
|
|
1726 Medical Blvd., Suite 101, Naples, Florida
|
|
34110
|
(Address of Principal Executive Offices)
|
|
(ZIP Code)
|
(239)
513-1992
(Registrant’s Telephone Number, Including
Area Code)
N/A
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the
following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☒
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on
which registered
|
|
|
|
|
|
|
|
|
|
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On April 30, 2019, HealthLynked Corp. (the
“
Company
”) appointed Robert Gasparini to its Board of Directors.
Mr. Gasparini started his career in the
genetics laboratories at the University of CT and became an assistant professor there from 1985-1990. From 1990-1993 he was Technical
Director of Genetics at Tufts and from 1993-1997 he was Assistant Director for the Prenatal Diagnostic Center in Lexington MA (a
Mass General affiliate). Mr. Gasparini also worked as a Manager of Worldwide and Strategic Marketing with Ventana Medical Systems
from 1998-2000 and in 2001, he became Director of Genetics for US Labs in Irvine California.
Mr. Gasparini’s career highlights
include:
|
●
|
Starting the Genetics Division at US Labs
and developing it into one of the largest programs in the US.
|
|
●
|
Recruited over 120 skilled team members
there, created and ran 4 departments including Cytogenetics, Flow Cytometry, FISH and Molecular Genetics.
|
|
●
|
Designed and developed the first fully
automated FISH laboratory in the US.
|
|
●
|
Developed the TargetGeneä concept
and all FISH panels for hematologic diseases.
|
|
●
|
Designed and established the concept of
cytogenetics “pods” or off-site satellite laboratories.
|
|
●
|
Helped develop Ventana Medical System’s
national and worldwide strategic marketing initiates for their new INFORM HER-2™ FISH Test, their new Pathway HER-2™
IHC test and their new BenchMarkä FISH/IHC instrument.
|
|
●
|
One of five individuals originally certified
by the FDA in 1998 for HER-2 FISH training.
|
|
●
|
23 years in the academic world including
17 years as director and professor.
|
|
●
|
Developed the first US genetic technology
education program at the Univ. of CT.
|
|
●
|
Helped develop the national certification
exam process (NCA) and the national accreditation process (NAACLS) for genetic technologists and genetic programs.
|
|
●
|
28 years of combined service on national
committees and Boards of Directors.
|
|
●
|
15 published peer-reviewed articles and
30+ published peer-reviewed abstracts.
|
|
●
|
Over 250 invited presentations across
North America; 4 international presentations.
|
|
●
|
14 national awards including the AGT Lifetime
Achievement Award (2000).
|
|
●
|
Mr. Gasparini was a key executive at NeoGenomics
Laboratories serving in many capacities with the company including President and Chief Scientific Officer as well as being on the
Board of Directors from 2004-2014.
|
Mr. Gasparini will receive stock compensation
with a value of $5,000 per quarter.
There is no arrangement or understanding
between Mr. Gasparini and any other persons pursuant to which he was selected as a director. Mr. Gasparini has no direct or indirect
material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d)
Exhibits
.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
HealthLynked Corp.
|
|
|
|
Dated: May 6, 2019
|
By:
|
/s/ George O’Leary
|
|
|
George O’Leary
|
|
|
Chief Financial Officer
|
2
HealthLynked (QB) (USOTC:HLYK)
Historical Stock Chart
From Apr 2024 to May 2024
HealthLynked (QB) (USOTC:HLYK)
Historical Stock Chart
From May 2023 to May 2024